Recent Development News: Q3 – 2014

Premier Alliance Gains Approval for Contracting With United States Department of Energy

New York, NY (September 12, 2014) – The United States Department of Energy (DOE) has added Premier Alliance (OTCQB: PIMO) to its list of Qualified Energy Service Companies, the company announced today. The decision by the DOE enables Premier Alliance … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

Medgenics Announces the Appointment of Scott Applebaum as Chief Legal Officer

WAYNE, Pa. and MISGAV, Israel, Sept. 10, 2014 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

ContraFect Corporation Announces Separation of Units Sold in IPO

YONKERS, NY — (Marketwired) — 09/09/14 — ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that the units issued in ContraFect’s recent initial public offering will separate on … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

Edge Therapeutics Obtains $10 Million Venture Loan Facility with Hercules Technology Growth Capital

BERKELEY HEIGHTS, N.J.– September 8, 2014 – Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions, today announced that it … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

ContraFect Corporation to Present at the Rodman & Renshaw 16th Annual Healthcare Conference

YONKERS, NY — (Marketwired) — 09/03/14 — ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that Julia P. Gregory, the Company’s chief executive officer and Barry Kappel, the … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

ContraFect Corporation Showcases CF-301 at ICAAC 2014 Meeting in Washington, D.C.

YONKERS, NY — (Marketwired) — 09/02/14 — ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, is pleased to announce that ContraFect has been selected to give an oral presentation at … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

Premier Alliance Group Elects Anthony Sartor to Board

New York, New York (August 25, 2014) – Anthony Sartor, chairman and chief executive officer of Paulus, Sokolowski and Sartor (PS&S), has been elected a Director of Premier Alliance Group, Inc. (OTCQB: PIMO), the company announced today. Dr. Sartor has … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

SpendSmart Networks YOY Growth Rate Catapults by 277% Leading Mobile Loyalty Solutions Company Celebrates Record Growth and Makes Significant Product Enhancements

SAN LUIS OBISPO, Calif., Aug. 19, 2014 (GLOBE NEWSWIRE) — via PRWEB – SpendSmart Networks Inc., (SSPC), a leading provider of mobile customer loyalty and merchant performance advertising solutions, today announced tremendous growth achievements. The company’s customer growth rate has … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

ContraFect Corporation Announces Closing of Initial Public Offering

YONKERS, NY — (Marketwired) — 08/04/14 — ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today that on August 1, 2014 it closed its initial public offering of 6,000,000 … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

ContraFect Announces Pricing of Its Initial Public Offering

ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, announced today the pricing of its initial public offering of 6,000,000 units priced at $6.00 per unit for total gross proceeds of … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

Cerecor Inc Closes on Initial Tranche of US$32M Series B Financing

Baltimore, MD, July 21, 2014 — Cerecor Inc, a clinical stage biopharmaceutical company developing innovative treatments to make a difference in the lives of patients suffering from nervous system disorders, today announced the closing of the first tranche of a $32M … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

Medgenics Reports Second Quarter Financial Results

WAYNE, Pa. and MISGAV, Israel, July 16, 2014 (GLOBE NEWSWIRE) — Medgenics, Inc. (NYSE MKT:MDGN) (the Company), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex vivo gene therapy and their own tissue for the treatment of … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

SpendSmart Network Surpasses 2 Million Subscribers, 125 Markets

  SAN LUIS OBISPO, Calif., July 10, 2014 (GLOBE NEWSWIRE) — via PRWEB – Publicly traded company SpendSmart Networks, Inc., (SSPC), a national leader in digital loyalty systems, announced today that it has surpassed two million mobile subscribers in their … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off

SpendSmart Networks, Inc. Launches New Corporate Website

SAN LUIS OBISPO, Calif., July 8, 2014 (GLOBE NEWSWIRE) — via PRWEB – Publicly traded company, SpendSmart Networks, Inc. (SSPC) launched its updated corporate website this week, spendsmartnetworks.com, in an effort to give the public greater insight into the corporate … Continue reading

Posted in Recent Development News: Q3 – 2014 | Comments Off